IN2015DN00585A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00585A
IN2015DN00585A IN585DEN2015A IN2015DN00585A IN 2015DN00585 A IN2015DN00585 A IN 2015DN00585A IN 585DEN2015 A IN585DEN2015 A IN 585DEN2015A IN 2015DN00585 A IN2015DN00585 A IN 2015DN00585A
Authority
IN
India
Prior art keywords
peptide
hexamer
cyclized
avoidance
natural
Prior art date
Application number
Inventor
Bernhard Fischer
Rudolf Lucas
Hendrik Fischer
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN00585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of IN2015DN00585A publication Critical patent/IN2015DN00585A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

What is described is a peptide which consists of 7-20, especially 7-17, adjacent amino acids and comprises the - hexamer TX 1EX 2X3E where Xi, X 2 and X3 may be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.
IN585DEN2015 2012-06-28 2013-06-19 IN2015DN00585A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12173983.3A EP2679239A1 (en) 2012-06-28 2012-06-28 Pharmaceutical compound for treating the pulmonary form of altitude sickness caused by oxygen deprivation and reduced air pressure
PCT/EP2013/062777 WO2014001177A1 (en) 2012-06-28 2013-06-19 Pharmaceutical composition for treatment of the pulmonary form of altitude sickness caused by lack of oxygen and reduced air pressure

Publications (1)

Publication Number Publication Date
IN2015DN00585A true IN2015DN00585A (en) 2015-06-26

Family

ID=48672620

Family Applications (1)

Application Number Title Priority Date Filing Date
IN585DEN2015 IN2015DN00585A (en) 2012-06-28 2013-06-19

Country Status (14)

Country Link
US (2) US9802985B2 (en)
EP (2) EP2679239A1 (en)
JP (1) JP6113277B2 (en)
KR (1) KR102010793B1 (en)
CN (1) CN104427993B (en)
AP (1) AP2014008162A0 (en)
AU (1) AU2013283563B2 (en)
CA (1) CA2875749C (en)
EA (1) EA030384B1 (en)
ES (1) ES2602197T3 (en)
IN (1) IN2015DN00585A (en)
MX (1) MX354302B (en)
PE (1) PE20150198A1 (en)
WO (1) WO2014001177A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3113786B1 (en) * 2014-03-04 2020-02-19 APEPTICO Forschung und Entwicklung GmbH Attenuation of intrapulmonary inflammation
CA2940351A1 (en) * 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
KR20180041749A (en) 2015-08-25 2018-04-24 바-일란 유니버시티 Asymmetric electrochemical cell device and its operation method
WO2018211474A1 (en) 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
EP4051311A4 (en) * 2019-10-29 2023-12-06 University of Pittsburgh - of the Commonwealth System of Higher Education Lung-specific targeting-peptide (ltp), compositions, and uses thereof
ES2938574T3 (en) 2020-05-08 2023-04-12 Apeptico Forschung & Entwicklung Gmbh Peptide for the prevention or treatment of COVID-19

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
WO1994018325A1 (en) 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
DE69938743D1 (en) 1998-08-14 2008-06-26 Rudolf Lucas TNF peptides for the treatment of edema
WO2006013183A1 (en) * 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (en) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick CYCLIC AND CYSTONE FREE PEPTIDE
TWI528982B (en) * 2009-03-04 2016-04-11 曼凱公司 An improved dry powder drug delivery system
AT507953B1 (en) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh METHOD FOR AVOIDING AND TREATING HYPERPERMEABILITY
AT509267A1 (en) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh ORGANIC COMPOUNDS FOR THE REGULATION OF VECTOR ION CHANNELS
AT510585B1 (en) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh COMPOSITION COMPRISING A PEPTIDE AND AN INHIBITOR OF VIRAL NEURAMINIDASE

Also Published As

Publication number Publication date
US20150225460A1 (en) 2015-08-13
CN104427993A (en) 2015-03-18
EP2679239A1 (en) 2014-01-01
CA2875749C (en) 2019-02-26
AU2013283563B2 (en) 2017-06-08
EP2866824A1 (en) 2015-05-06
AU2013283563A1 (en) 2015-01-15
JP2015526399A (en) 2015-09-10
MX2014015048A (en) 2015-06-05
ES2602197T3 (en) 2017-02-20
EA201500061A1 (en) 2015-06-30
US20190211061A1 (en) 2019-07-11
WO2014001177A1 (en) 2014-01-03
PE20150198A1 (en) 2015-02-19
JP6113277B2 (en) 2017-04-12
CN104427993B (en) 2017-03-08
US9802985B2 (en) 2017-10-31
CA2875749A1 (en) 2014-01-03
EA030384B1 (en) 2018-07-31
EP2866824B1 (en) 2016-08-10
KR20150037815A (en) 2015-04-08
AP2014008162A0 (en) 2014-12-31
MX354302B (en) 2018-02-23
KR102010793B1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
IN2015DN00585A (en)
AU2018260800A1 (en) Hepcidin analogues and uses therof
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX2012009748A (en) Use of transforming growth factor - beta 1 (tgf-î²1) inhibitor peptides for the treatment of corneal fibrosis and/or haze.
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
MX2019011592A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
UA118167C2 (en) Peptides and their use
EP3638298A4 (en) Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
EP2686688A4 (en) Systems and compositions for diagnosing barrett's esophagus and methods of using the same
MX2013004190A (en) Compositions and methods of treating pulmonary hypertension.
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
EP3624831A4 (en) Recombinant human acid alpha-glucosidase
SG10201901656WA (en) Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof
EP3909975A4 (en) Novel polypeptide and therapeutic uses thereof
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
EP2552462A4 (en) Ccn3 peptides and analogs thereof for therapeutic use
WO2013021284A3 (en) Anti-il-6 vaccine composition
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
WO2015009820A3 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2012019086A3 (en) Inhibition of lar phosphatase to enhance therapeutic angiogenesis
WO2009158238A3 (en) Fibroblast growth factor (fgf) analogs and uses thereof
PH12015502072B1 (en) Nutritional compositions containing a peptide component and uses thereof
HUE061288T2 (en) Formulations comprising active oxygen
MX2021006488A (en) Compositions for improving sexual function.